1. Home
  2. PBT vs MLYS Comparison

PBT vs MLYS Comparison

Compare PBT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

HOLD

Current Price

$35.21

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.97

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBT
MLYS
Founded
1980
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
2.5B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
PBT
MLYS
Price
$35.21
$27.97
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$48.67
AVG Volume (30 Days)
88.1K
1.1M
Earning Date
03-13-2026
05-06-2026
Dividend Yield
1.50%
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$57.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$22.30
52 Week High
$37.00
$47.65

Technical Indicators

Market Signals
Indicator
PBT
MLYS
Relative Strength Index (RSI) 64.00 50.33
Support Level $32.75 $25.56
Resistance Level N/A $28.14
Average True Range (ATR) 0.86 1.68
MACD -0.10 -0.06
Stochastic Oscillator 62.75 39.69

Price Performance

Historical Comparison
PBT
MLYS

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: